Tasly Holding Group Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
10,563
- Stock Symbol
-
600535
- Investments
-
56
- Share Price
-
$2.10
- (As of Friday Closing)
Tasly Holding Group General Information
Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
Contact Information
Website
www.tasly.comCorporate Office
- Number 2, Pujihe East Road
- Beichen District
- Tianjin, 300410
- China
Corporate Office
- Number 2, Pujihe East Road
- Beichen District
- Tianjin, 300410
- China
Tasly Holding Group Stock Performance
As of 13-Nov-2026, Tasly Holding Group’s stock price is $2.10. Its current market cap is $3.13B with 1.49B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.10 | $2.09 | $1.90 - $2.40 | $3.13B | 1.49B | 12.8M | $0.12 |
Tasly Holding Group Financials Summary
As of 30-Sep-2026, Tasly Holding Group has a trailing 12-month revenue of $1.16B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,719,513 | 2,869,575 | 2,618,562 | 3,503,180 |
| Revenue | 1,160,571 | 1,145,336 | 1,184,334 | 1,226,030 |
| EBITDA | 207,539 | 246,691 | 213,940 | 240,426 |
| Net Income | 177,458 | 153,652 | 133,174 | 151,391 |
| Total Assets | 2,247,299 | 2,192,422 | 2,051,519 | 2,357,911 |
| Total Debt | 27,213 | 205,582 | 226,838 | 386,524 |
Tasly Holding Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tasly Holding Group Patents
Tasly Holding Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233184-A1 | Bispecific chimeric antigen receptor and use thereof | Pending | 09-May-2025 | ||
| WO-2026200003-A1 | Peg-hmfgf-21 injection, preparation method therefor, and use thereof | Pending | 26-Mar-2025 | ||
| WO-2026092393-A1 | Mesenchymal stromal cell-based drug and use thereof in treatment of acute cerebral infarction | Pending | 28-Oct-2024 | ||
| WO-2024022173-A1 | Use of andrographolide and composition thereof in preparation of drug for treating hearing impairment | Inactive | 29-Jul-2022 | ||
| US-20250075172-A1 | Production method for bispecific antibody | Pending | 24-Dec-2021 | C12N5/0018 |
Tasly Holding Group Signals
Tasly Holding Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tasly Holding Group Investments & Acquisitions (56)
Tasly Holding Group’s most recent deal was a Early Stage VC with Rui Therapeutics for . The deal was made on 15-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Rui Therapeutics | 15-Sep-2025 | Early Stage VC | Drug Discovery | ||
| Ribopeutic | 10-Aug-2025 | Early Stage VC | Drug Discovery | ||
| Singular Medical | 04-Feb-2025 | Later Stage VC | Diagnostic Equipment | ||
| LMBio | 10-Dec-2024 | Early Stage VC | Biotechnology | ||
| Synceres Biosciences | 15-Jun-2023 | Early Stage VC | Drug Discovery |
Tasly Holding Group ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Tasly Holding Group Exits (18)
Tasly Holding Group’s most recent exit was on 06-Jul-2022 from ClouDr.. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| ClouDr. | 06-Jul-2022 | Completed |
|
||
| HeartCare Medical | 14-May-2020 | Completed |
|
||
| ClouDr. | 08-Jan-2020 | Completed |
|
||
| ClouDr. | 01-Sep-2019 | Completed |
|
||
| NovaBridge Biosciences | 06-Jul-2018 | Later Stage VC | Completed |
|
Tasly Holding Group Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Tasly Sainte Pharmaceutical | Tianjin, China | 2007 | |
| Tasly Capital | Beijing, China | 2007 |
Tasly Holding Group FAQs
-
When was Tasly Holding Group founded?
Tasly Holding Group was founded in 1994.
-
Where is Tasly Holding Group headquartered?
Tasly Holding Group is headquartered in Tianjin, China.
-
What is the size of Tasly Holding Group?
Tasly Holding Group has 10,563 total employees.
-
What industry is Tasly Holding Group in?
Tasly Holding Group’s primary industry is Pharmaceuticals.
-
Is Tasly Holding Group a private or public company?
Tasly Holding Group is a Public company.
-
What is Tasly Holding Group’s stock symbol?
The ticker symbol for Tasly Holding Group is 600535.
-
What is the current stock price of Tasly Holding Group?
As of 13-Nov-2026 the stock price of Tasly Holding Group is $2.10.
-
What is the current market cap of Tasly Holding Group?
The current market capitalization of Tasly Holding Group is $3.13B.
-
What is Tasly Holding Group’s current revenue?
The trailing twelve month revenue for Tasly Holding Group is $1.16B.
-
What is Tasly Holding Group’s annual earnings per share (EPS)?
Tasly Holding Group’s EPS for 12 months was $0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process